undamentalytics Newsletter
Sign in

Anika Therapeutics, Inc. balance sheet

At the end of fiscal 2025, Anika Therapeutics, Inc. had total assets of $190m and shareholders' equity of $143m. It held $57.5m in cash against $0 of debt: net cash of $57.5m.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2009Dec 20092010Dec 20102011Dec 20112012Dec 20122013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash and equivalents24283644631001111041338915796948669565738
Receivables—1517211917222824212324303526242429
Inventory—9781112151622212246364024241929
Total current assets—5664779513817617020620323417716917016311410399
Goodwill—99998778888878788
Total assets—129133142156193236240283279331366348349271203190183
Accounts payable—104231827349896666
Deferred revenue (current)—33300——————————00
Total current liabilities—1915149617913111637302831232222
Short-term debt—222——————————————
Long-term debt—11108——————0———————
Total debt0131110800000025000000
Shareholders' equity828595109136178211223263264288272287286212154143137
Net debt (negative = net cash)−24−15−25−34−55−100−111−104−133−89−157−71−94−86−69−56−57−38
Shares outstanding—13m14m14m14m15m15m15m15m14m14m14m14m15m15m14m14m13m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: ANIK vs OMANIK vs OWLTANIK vs BBNXANIK vs RXST

More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies

Figures from Anika Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Anika Therapeutics, Inc.